MRC & RCOphth John Lee Fellowship

 

John Lee

        JOHN LEE FELLOWSHIP BROCHURE

 

The eighth President of the College, Mr John Lee, died during his presidency, which was an enormous loss. The College intends to commemorate his outstanding contribution to the ophthalmic profession by creating a named Research Fellowship jointly funded by the Medical Research Council and the College. This is a particularly apt memorial for he was a strong advocate of academic medicine. The Fellowship is likely to begin in 2012 and we are actively seeking contributions to pay our share of the costs which are expected to be in the order of £125,000.

 

 

 

 

 

 

 

If you would like to make a contribution to this fund you may do so in one of the following ways:

By downloading a Gift Aid Form

By making a donation through our JustGiving page http://www.justgiving.com/rcophth/donate

 

Donate with JustGiving


John's Obituary from College News can be downloaded.  Mr Richard Harrad has written an obituary for the journal Strabismus which can be viewed at http://informahealthcare.com/doi/full/10.3109/09273972.2010.534028

 

The first MRC/John Lee Fellowship has been awarded to Dr Peter Morgan-Warren.

Dr Peter Morgan-WarrenProject Summary

 

The research to be undertaken will investigate the possibility of developing a molecular treatment to promote regeneration of nerves in the visual system following damage to the optic nerve. Several conditions may cause optic nerve damage, including traumatic optic neuropathy, glaucoma and ischaemic injury, and these can cause severe visual impairment. Once optic nerve damage has occurred, the neurons die and there are currently no effective treatments available to reverse the process and restore vision.  Through manipulation of cellular signalling pathways, we aim to develop a molecule to allow survival of optic nerve cells following injury, and promote regeneration of neurons in order to restore visual function. If successful, this may be translated into new therapies and offer hope for patients who have lost vision from optic nerve conditions.

 

Nemisys